Arbutus Biopharma Files 8-K on Financial Condition

TL;DR

**Arbutus Biopharma just dropped an 8-K, signaling an update on their financial health and operations.**

AI Summary

Arbutus Biopharma Corporation filed an 8-K on February 29, 2024, reporting on its financial condition and other events. The company, incorporated in British Columbia, Canada, with IRS Employer Identification No. 98-0597776, operates from 701 Veterans Circle, Warminster, Pennsylvania. This filing, under SEC File Number 001-34949, indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing provides an update on Arbutus Biopharma's operational and financial status, offering transparency to investors and the market regarding its current business activities.

Risk Assessment

Risk Level: low — The 8-K filing itself is a routine disclosure and does not inherently indicate a high risk, but rather provides information.

Key Players & Entities

• Arbutus Biopharma Corporation (company) — registrant
• British Columbia, Canada (company) — state or other jurisdiction of incorporation
• 001-34949 (dollar_amount) — Commission File Number
• 98-0597776 (dollar_amount) — I.R.S. Employer Identification No.
• 701 Veterans Circle Warminster , Pennsylvania 18974 (company) — Address of Principal Executive Offices
• February 29, 2024 (dollar_amount) — Date of earliest event reported

FAQ

Filing Documents

• f8k_022924.htm (8-K) — 15KB
• exh_991.htm (EX-99.1) — 79KB
• exh_992.htm (EX-99.2) — 44KB
• exh992_01.jpg (GRAPHIC) — 118KB
• exh992_02.jpg (GRAPHIC) — 274KB
• exh992_03.jpg (GRAPHIC) — 106KB
• exh992_04.jpg (GRAPHIC) — 169KB
• exh992_05.jpg (GRAPHIC) — 90KB
• exh992_06.jpg (GRAPHIC) — 128KB
• exh992_07.jpg (GRAPHIC) — 172KB
• exh992_08.jpg (GRAPHIC) — 118KB
• exh992_09.jpg (GRAPHIC) — 138KB
• exh992_10.jpg (GRAPHIC) — 119KB
• exh992_11.jpg (GRAPHIC) — 288KB
• exh992_12.jpg (GRAPHIC) — 235KB
• exh992_13.jpg (GRAPHIC) — 127KB
• exh992_14.jpg (GRAPHIC) — 142KB
• exh992_15.jpg (GRAPHIC) — 241KB
• exh992_16.jpg (GRAPHIC) — 159KB
• exh992_17.jpg (GRAPHIC) — 245KB
• exh992_18.jpg (GRAPHIC) — 208KB
• exh992_19.jpg (GRAPHIC) — 116KB
• exh992_20.jpg (GRAPHIC) — 138KB
• exh992_21.jpg (GRAPHIC) — 150KB
• exh992_22.jpg (GRAPHIC) — 127KB
• exh992_23.jpg (GRAPHIC) — 158KB
• exh992_24.jpg (GRAPHIC) — 121KB
• exh992_25.jpg (GRAPHIC) — 101KB
• exh992_26.jpg (GRAPHIC) — 100KB
• 0001171843-24-001068.txt ( ) — 5989KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_022924_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 29, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023 and certain other information. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

01. Other Events

Item 8.01. Other Events. On February 29, 2024, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 29, 2024 99.2 Corporate Presentation dated February 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: February 29, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR